Detalhe da pesquisa
1.
The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer.
Eur J Nucl Med Mol Imaging
; 45(2): 170-178, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28940101
2.
Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status.
BMC Cancer
; 14: 824, 2014 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25380690
3.
Class III ß-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
BMC Cancer
; 13: 431, 2013 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24053422
4.
Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer.
Oncol Lett
; 14(2): 2491-2498, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28781687
5.
Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients.
Asia Pac J Clin Oncol
; 13(1): 53-60, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27488933
6.
The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis.
Oncotarget
; 8(39): 66559-66568, 2017 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29029536
7.
A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Cancer Chemother Pharmacol
; 77(3): 605-12, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26846507
8.
A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting.
Biomed Res Int
; 2015: 523601, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26421292